English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, January 10, 2020
中國抗體榮獲「最受投資者歡迎新股公司」大獎
SinoMab Granted the "Most Popular Newly Listed Company" Award
Wednesday, November 20, 2019
类风湿关节炎治疗市场蓝海潜力巨大 中国抗体公布在研药物SM03类风湿关节炎III期临床试验最新进展
類風濕關節炎治療市場藍海潛力巨大 中國抗體公佈在研藥物SM03類風濕關節炎III期臨床試驗最新進展
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA
Monday, November 11, 2019
中国抗体(3681.HK):商业化进程未来可期
中國抗體(3681.HK):商業化進程未來可期
Wednesday, October 30, 2019
中国抗体制药宣布于港交所主板上市计划
中國抗體製藥宣佈於港交所主板上市計劃
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK

Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575